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Background. Gestational diabetes (GDM) affects up to 7% of pregnant women and is associated with several maternal and perinatal
morbidities. International organizations suggest several different recommendations regarding how to screen and to manage GDM.
Objective. We aimed to analyze the most important and employed guidelines about screening and management of GDM and we
investigated existing related literature. Results. We found several different criteria for screening for GDM, for monitoring GDM,
and for starting pharmacological therapy. When using IADPSG criteria, GDM rate increased, perinatal outcomes improved, and
screening became cost-effective. Compared to no treatment, treatment of women meeting criteria for GDM by IADPSG criteria
but not by other less strict criteria has limited evidence for an effect on adverse pregnancy outcomes.

1. Introduction
Gestational diabetes (GDM) can be broadly defined as
glucose intolerance during pregnancy that affects women
without previous diagnosis of diabetes or unknown state.
The incidence is about 7% worldwide and this rate has
been growing during the last decades and is estimated to
increase in the future. The most important risk factors are
maternal overweight and obesity, age greater than or equal
to 35 years at delivery, hypertension, metabolic syndrome,
nonwhite ethnicity, family history of diabetes mellitus, prior
unexplained stillbirth, prior infant with congenital anomaly
(if not screened during that pregnancy), prior macrosomic
infant, history of gestational diabetes, chronic use of steroids,
glycosuria, and known impaired glucose metabolism [1].
The importance of GDM is linked to the consequences
of pregnancy and also after pregnancy to both mother and
newborn. Hyperglycemia in the mother causes abnormal

metabolism while in the fetus it causes hyperinsulinemia and
its consequences, and incidence of complications is inversely
proportional to glucose control. Macrosomia, polyhydramnios, operative delivery, shoulder dystocia, birth injury,
perinatal mortality, hypertensive disorders and preeclampsia,
congenital malformations (OR: 1.2–1.4), and risk of cesarean
delivery are higher in women with GDM; in the long term,
women with GDM have a higher risk of developing type
2 diabetes mellitus and cardiovascular diseases; long-term
sequelae for offspring are obesity and metabolic syndrome.
Approximately 50% of women identified as having GDM will
develop frank diabetes within 10 years [2].
To prevent or decrease the risk of GDM, weight loss
before pregnancy and cardiovascular exercise could be useful.
In fact, aerobic exercise for 35–90 minutes 3-4 times per
week during pregnancy is associated with a significantly
higher incidence of vaginal delivery and a significantly lower
incidence of cesarean delivery, with a significantly lower
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incidence of gestational diabetes mellitus and hypertensive
disorders [3]. Prompt diagnosis and management are important to reduce worse pregnancy outcomes.
Nonetheless, screening, management, and follow-up of
GDM are controversial on international organizations recommendations.

2. Screening Controversies
The aim of screening is to identify asymptomatic pregnant
women at high risk of developing GDM. Screening appears
to be cost-effective for prevention of obstetrical adverse
outcomes and long-term consequences of GDM [4].
Regarding the effect of screening [1] on obstetrical outcomes, there are many controversies:
(a) Indications for screening (who): universal versus
selective screening
(b) Timing of screening (when): early screening versus at
24–28 weeks
(c) Type of screening (how): One- versus Two-Step
(d) Criteria for diagnosis: recommendations of international organizations are not standardized
(a) The population to screen has not been uniformly
identified. There are two possible approaches.
(i) Selective Screening. Only women with risk factor for GDM
are offered to be screened, that is, age > 25 years; ethnic origin
Hispanic, African, Native American, South or East Asian,
or Pacific Islander; BMI > 25; previous personal or family
history of impaired glucose tolerance; or history of adverse
obstetric outcomes associated with GDM.
(ii) Universal Screening. All women are subjected to screening;
in developed countries where overweight and obesity are
widespread health problems, this could be the best choice to
avoid undiagnosed GDM.
Universal screening is the most commonly adopted
method in the USA, while in other countries such as Italy the
selective approach is preferred [5].
(b) When identifying the population, it is essential to
decide the right time to screen.
Women with risk factors and high suspicion of undiagnosed type 2 DM (i.e., obesity, metabolic syndrome) should
be screened before pregnancy or at the first prenatal visit
(early screening). About 5–10% of women with risk factors
have early GDM, and these represent 40% of all women with
GDM.
In the absence of early screening or for women negative
to early screen, universal screening should be performed at
24 to 28 weeks.
(c) Now we discuss how to screen.
Screening for GDM is somewhat controversial and can
be performed either with a One-Step or with a Two-Step
approach.
(i) One-Step Approach. GDM screening is performed as an
oral 75 g glucose load followed by glucose blood measurement 1 and 2 hours later. A positive result is defined as one

value higher than target values. This approach is based on
HAPO study [6] and is suggested by IADPSG [7], WHO [8],
FIGO [5], and ADA [9]. In fact, HAPO study in 2008 demonstrated a direct correlation between maternal glucose levels
and increased birth weight and neonatal hyperinsulinemia.
(ii) Two-Step Approach. GDM is performed as a 50 g onehour oral glucose load (glucose challenge test, GCT), given
to nonfasting women, with a venous glucose measurement
one hour later. A positive result is defined as a blood glucose
value higher than 130, 135, or 140 mg/dL; the most common
value used is 135 mg/dL (ACOG) [4]. Positive screening test
is followed by a diagnostic test as an oral glucose tolerance
test (GTT) that consists of a beverage with 100 g of glucose,
with venous glucose measurement at fasting and after 1, 2,
and 3 hours. A positive result is defined as 2 values higher
than target values.
(d) Recommendations of international organizations are
not standardized.
Table 1 shows the different populations and times to
screen and the thresholds used by the most important
international organizations worldwide, updated to the latest
recommendations [4, 5, 8–12].
We found a large number of studies in international
literature comparing One-Step and Two-Step test and different glucose thresholds. When evaluating the best screening
method, clinically significant improvements in maternal
and neonatal outcomes were analyzed. Two are the most
significant studies:
(1) Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group: the aim was to
determine whether treatment of GDM reduced the
risk of perinatal complications.
(2) National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units
(MFMU) Network Study: the intent was to determine
whether treatment of women with mild GDM reduces
perinatal and obstetrical complications.
Both trials agree with the rule of IADPSG criteria adoption on reducing fetal birth weight over the 90th percentile
and the risk of developing maternal preeclampsia.
Furthermore, to compare the One-Step test to the TwoStep test, several possible study designs have been evaluated
in the literature. We can summarize the literature in five
groups.
(1) RCTs in which women underwent both the One-Step
and the Two-Step tests and the women positive for the OneStep but negative for the Two-Step test were randomized to
treatment of GDM versus no treatment: the only such RCT is
by Weiss et al. [12], who unfortunately do not report outcomes
specific to this group of women.
(2) RCTs of treatment versus no treatment of GDM,
focusing on women positive for the One-Step but negative
for the Two-Step test: we found 6 RCTs comparing insulin
or glyburide to placebo or routine care, and all of them
used a Two-Step approach with different glucose thresholds
(Table 2) [13–18]. In this group, ACHOIS trial by Crowther
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Table 1: Criteria for GDM screening and diagnosis.

Population to
screen

ACOG 2013 C&C [4]
ACOG 2013 NDDG [4]
ADA 2015 [9]
ADA 2015 [9]
ADIPS 2013 [52]
CDA 2013 [10]
FIGO 2013 [5]
IADPSG 2010 [7]
NICE 2015 [11]
WHO 2013 [8]

Selective
screening
Selective
screening
Universal
screening
Universal
screening
Selective
screening
Universal
screening
Universal
screening
Universal
screening
Selective
screening
Universal
screening

Time to screen

First visit
First visit
24–28 weeks
First visit
24–28 weeks
First visit
24–28 weeks
24–28 weeks
24–28 weeks
24–28 weeks

Test

Number of
abnormal
values
required
for
diagnosis

Fasting
glucose
(mg/dL)

1 hour
after
loading
(mg/dL)

2 hours
after
loading
(mg/dL)

3 hours
after
loading
(mg/dL)

≥2

95

180

155

140

≥2

105

190

165

145

≥2

95

180

155

Not
required

≥2

95

180

155

140

≥1

92

180

153

≥2

95

191

160

≥1

92

180

153

≥1

92

180

153

≥1

101

Not
required

140

≥1

92

180

153

Two-Step, 3 h,
100 g
Two-Step, 3 h,
100 g
One-Step, 2 h,
75 g
Two-Step, 3 h,
100 g
One-Step, 2 h,
75 g
Two-Step, 2 h,
75 g
One-Step, 2 h,
75 g
One-Step, 2 h,
75 g
One-Step, 2 h,
75 g
One-Step, 2 h,
75 g

Not
required
Not
required
Not
required
Not
required
Not
required
Not
required

ACOG: American College of Obstetricians and Gynecologists; ADA: American Diabetes Association; ADIPS: Australasian Diabetes in Pregnancy Society;
CDA: Canadian Diabetes Association; C&C: Carpenter and Coustan; FIGO: International Federation of Gynecology and Obstetrics; IADPSG: International
Association of Diabetes Pregnancy Study Group; NICE: National Institute for Health and Care Excellence; NDDG: National Diabetes Data Group; WHO:
World Health Organization.

Table 2: RCTs of treatment versus no treatment of GDM, focusing on women positive for the One-Step but negative for the Two-Step test.
Study
O’Sullivan et al.,
1966 (USA) [13]
Coustan and
Lewis, 1978 (USA)
[14]
Thompson et al.,
1990 (USA) [15]
Crowther et al.,
2005 (Australia)
[16]
Landon et al., 2009
(USA) [17]
Casey et al., 2015
(USA) [18]

Screening test

Diagnostic test

Values for
diagnosis

Intervention
group

Control
group

Primary
outcome

50 g GCT: positive
if ≥130 mg/dl

100 g, 3 h
(110-170-120-110)

2 or more values

Insulin

Routine care

LGA

50 g GCT: positive
if ≥130 mg/dl

100 g, 3 h
(95-180-160-135)

2 or more values

Insulin

Routine care

Macrosomia

50 g GCT: positive
if F > 105 mg/dL or
1 h > 140 mg/dL

100 g, 3 h
(105-190-165-145)

2 or more values

Insulin

Routine care

Maternal and
neonatal
morbidity

Both values

Insulin

Routine care

Perinatal
complications

2 or more values
but F < 95 mg/dL

Insulin

Routine care

Perinatal
outcome

2 values

Glyburide

Placebo

Birth weight

50 g GCT: positive
if ≥140 mg/dl
50 g GCT: positive
if ≥135 mg/dl
50 g GCT: positive
if ≥140 mg/dL

75 g OGTT
(F > 7.8; 2 h
7.8–10 mmol/L)
100 g, 3 h
(95-180-155-140)
100 g, 3 h
(105-190-165-145)

et al. [16] is included, mentioned before. The main common
outcome was lower rate of fetal birth weight over the 90th
percentile and macrosomia.
(3) RCTs comparing the One-Step to the Two-Step
methods: we found 3 RCTs by Meltzer et al. [19], Sevket et al.
[20], and Scifres et al. [21] (Table 3). In each one, there are

a study group undergoing One-Step 75 g test and a control
group undergoing Two-Step 100 g test. Regarding GDM rate,
Sevket et al.’s and Scifres et al.’s RCTs reveal an incidence more
than double in the study group with respect to control group
(14.5% versus 6%; 4.3% versus 0.0%), while in Meltzer et al.’s
RCT, there are no differences (3.6% versus 3.7%). Maternal
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Table 3: RCTs comparing the One-Step to the Two-Step methods.

Author (origin)
Meltzer et al., 2010
(Canada) [19]
Sevket et al., 2013
(Turkey) [20]
Scifres et al., 2014
(USA) [21]

Study group
One-Step (2 h, 75 g)
One-Step (2 h, 75 g)
One-Step (2 h, 75 g)

Control group (1)
Two-Step (50 g, 1 h;
100 g, 3 h)
Two-Step (50 g, 1 h;
100 g, 3 h)
Two-Step (50 g, 1 h;
100 g, 3 h)

and neonatal outcomes have been analyzed only in 2 studies.
Sevket et al.’s RCT reveals that GDM-negative women by
IADPSG had better perinatal outcomes than GCT-negative
women and GCT-positive women with a negative OGTT;
Scifres et al.’s RCT concludes that rates of macrosomia,
cesarean delivery, and pregnancy-induced hypertension were
also similar between groups.
Interestingly, Meltzer et al.’s RCT analyzed costs of the
One-Step compared to the Two-Step test: while the Two-Step
test involved the lowest costs, the One-Step test recognized
higher GDM rate. The authors’ conclusion was in favor of the
Two-Step test because the universal glucose screen with 50 g
glucose load is an inexpensive, easy-to-administer tool for
GDM screening, especially with the use of a lower diagnostic
cut-off.
(4) Prospective non-RCTs or retrospective studies comparing incidence of GDM and/or outcomes between the OneStep and Two-Step methods: we found 9 retrospective studies
comparing the One-Step approach with IADPSG criteria and
Two-Step approach with ACOG criteria (Table 4) [22–30].
Regarding GDM rate, the incidence is higher for women
undergoing the One-Step test in all the studies analyzing this
issue. Only two studies concluded that IADPSG One-Step
approach is useful to avoid worse pregnancy outcomes, in
particular LGA and macrosomia [22, 27], while five studies
did not find statistically significant differences between the
two approaches on outcomes [23–26, 28].
(5) Prospective non-RCTs or retrospective studies reporting outcomes of women meeting criteria for GDM based
on the One-Step test but not on the Two-Step test: we
found 8 retrospective cohort studies (Tables 5 and 6) [31–
38], but no study evaluated whether treatment of women
meeting criteria for GDM by IADPSG criteria (One-Step
test) but not by other less strict criteria has an effect on
adverse pregnancy outcomes compared to no treatment.
When analyzing outcomes, macrosomia was more common
in women positive on 75 g IADPSG criteria but negative
on CDA criteria and positive on 75 g IADPSG criteria but
negative on NICE criteria.

3. Conclusion
Despite continuing controversy regarding whether the OneStep test or the Two-Step test should be used for GDM screening, we identified very limited evidence regarding whether
treatment of women meeting criteria for GDM by IADPSG
criteria (One-Step test) but not by other less strict criteria
has an effect on adverse pregnancy outcomes compared to no

Control group (2)
Two-Step (50 g, 1 h;
75 g, 3 h)

GDM rate
3.6% versus 3.7%
versus 3.7%
14.5% versus 6%
4.3% versus 0.0%

Primary outcome
Costs of screening
Maternal and
neonatal outcomes
Maternal and
neonatal outcomes

treatment. Moreover, in none of the included studies was the
study group with milder disease treated for GDM (positive
for IADPSG criteria, but negative for less stringent criteria).
We also found a large variety of different criteria (IADPSG,
WHO, NICE, CDA, and C&C) for screening for GDM used
in the literature. Therefore, it is not surprising that societies
such as IADPSG, WHO, and FIGO recommend the OneStep approach (assuming that identification of women with
milder GDM might have benefits for them and their babies),
while others such as ACOG still recommend the Two-Step
approach for screening.
Only well designed RCTs comparing the One-Step versus
the Two-Step approach including huge populations could
answer this question.

4. Management Controversies
The aim of management is to reduce the risk of adverse
outcomes for the mother and the fetus. Several studies
demonstrated that treatment can be effective in reducing
adverse outcomes in GDM patients.
Regarding the effect of management on obstetrical outcomes, there are many variables that can play a role; these
include
(i) criteria to start therapy after diet alone: once GDM
has been diagnosed, patients start nonpharmacological therapy, that is, well balanced diet based on BMI
and physical exercise, but it is unclear how long
this evaluation period should last before deciding to
start pharmacological treatment; a recent systematic
review found inconclusive evidence for the threshold
value to start medical therapy [4];
(ii) type of initial therapy: insulin and oral hypoglycemic
agents are equally effective and can be used as firstline therapy [5];
(iii) dose and frequency of initial therapy: therapy should
start at the lower effective dose and then increase
based on glucose monitoring;
(iv) frequency of glucose monitoring: when patients start
therapy, either diet or pharmacological therapy is
important to establish whether glycemic control has
been reached; while patients in pharmacological therapy should perform glycemic checks at least four
times daily (fasting and after 1 or 2 hours from
three main meals: breakfast, lunch, and dinner), there
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Table 4: Prospective non-RCTs or retrospective studies comparing incidence of GDM and/or outcomes between the One-Step and Two-Step
methods.
Author (origin)

Study design

Duran et al., 2014
(Spain) [22]

Retroprospective
cohort

Fuller and Borgida,
2014 (USA) [23]

Retroprospective
cohort

Liu et al., 2014
(China) [24]

Retrospective cohort

Oriot et al., 2014
(Belgium) [25]

Retrospective cohort

Wei et al., 2014
(China) [26]

Retrospective cohort

Hung and Hsieh,
2015 (Taiwan) [27]

Retrospective cohort

Kong et al., 2015
(Canada) [28]

Retrospective cohort

Assaf-Balut et al.,
2016 (Spain) [29]

Retrospective cohort

Klara Feldman et al.,
2016 (USA) [30]

Retroprospective
cohort

Two-Step group
ACOG: 50 g 1 h
GCT; if >140 mg/dL
followed by 100 g 3 h
GTT (C&C)
ACOG: 50 g 1 h
GCT; if >135 mg/dL
followed by 100 g 3 h
GTT (C&C)
ACOG: 50 g 1 h
GCT; if >140 mg/dL
followed by 100 g 3 h
GTT (C&C)
ACOG: 50 g 1 h
GCT; if >140 mg/dL
followed by 100 g 3 h
GTT (C&C)
ACOG: 50 g 1 h
GCT; if >135 mg/dL
followed by 75 g 3 h
GTT (NDDG)
ACOG: 50 g 1 h
GCT; if >140 mg/dL
followed by 100 g 3 h
GTT (C&C)
ACOG: 50 g 1 h
GCT; if >140 mg/dL
followed by 100 g 3 h
GTT (C&C)
ADA: 50 g 1 h GCT;
if >140 mg/dL
followed by 100 g 3 h
GTT (C&C)
ACOG: 50 g 1 h
GCT; if >130 mg/dL
followed by 100 g 3 h
GTT (C&C)

is uncertainty for women in nonpharmacological
therapy [5];
(v) target glucose values: RCTs to identify ideal glycemic
targets have not been performed, but ADA and
ACOG recommend a threshold of 140 mg/dL at 1 hour
postprandially or 120 mg/dL at 2 hours postprandially
as glycemic targets to reduce the risk of macrosomia
[5, 9];
(vi) criteria for pharmacologic therapy dose adjustment:
when choosing between tight versus very tight
glycemic control, we have to consider risk of hypoglycemia, effects of non-well-controlled GDM, and
women compliance;
(vii) criteria for adding or switching pharmacologic therapy;
(viii) fetal monitoring;

One-Step group

GDM rate

Primary outcome

IADPSG: 75 g 2 h
GTT

10.6% versus 35.5%

Pregnancy outcomes

IADPSG: 75 g 2 h
GTT

7.0% versus 11.7%

Maternal and
delivery outcomes

IADPSG: 75 g 2 h
GTT

7.0% versus 20.4%

Maternal and
perinatal outcomes

IADPSG: 75 g 2 h
GTT

8.0% versus 23.0%

CS, macrosomia

IADPSG: 75 g 2 h
GTT

18.3% versus 21.0%

CS, macrosomia

IADPSG: 75 g 2 h
GTT

4.6% versus 12.4%

Macrosomia, LGA

IADPSG: 75 g 2 h
GTT

7.9% versus 9.4%

Maternal and fetal
outcomes

IADPSG: 75 g 2 h
GTT

Not stated

Postpartum
disorders

IADPSG: 75 g 2 h
GTT if HbA1c <
5.7%

17.0% versus 27.0%

Pregnancy outcomes

(ix) time to delivery: women with GDM with good
glycemic control and no other complications can
be managed expectantly, while if GDM is not well
controlled with therapy, induction of delivery could
be considered [5].
We analyzed the literature to figure out which management is the best to follow. When evaluating RCTs [16, 17,
39–51] which included criteria for starting pharmacologic
therapy in women with GDM, the most common frequency
for glucose monitoring was four times per day (i.e., when
fasting and after each main meal). The effect of therapy
on GDM was assessed using fasting of 90 (or 95) mg/dL
and 2 hours of 120 mg/dL as blood glucose target values.
Importantly, we found several different criteria for starting
pharmacologic therapy after a period of diet alone, with the
majority using very tight criteria of either 1 or 2 values in oneor two-week period higher than the target values, of which
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Table 5: Prospective non-RCT or retrospective studies reporting outcomes of women meeting criteria for GDM based on the One-Step test
but not on the Two-Step test.
Author (origin)

Study design

GDM screening

50 g GCT criteria

75 g OGTT criteria

Lapolla et al., 2011
(Italy) [31]

Retrospective cohort

Two-Step: 50 g 1 h; if
>140 mg/dL: 100 g
3 h GTT

≥140 mg/dL: 100 g
3 h GTT

Not done

Bodmer-Roy et al.,
2012 (Canada) [32]

Retrospective cohort

Two-Step: 50 g 1 h; if
137–184 mg/dL: 75 g
2 h GTT

137–184 mg/dL: 75 g
GTT;
>184 mg/dL: GDM

1 abnormal value of
fasting ≥ 96 mg/dL;
1 h: ≥191 mg/dl; 2 h:
≥160 mg/dL∗

Benhalima et al.,
2013 (Belgium) [33]

Retrospective cohort

Two-Step: 50 g 1 h; if
≥140 mg/dL:100 g 3 h
GTT

≥140 mg/dL: 100 g
3 h GTT

Not done

Ethridge et al., 2014
(USA) [34]

Retrospective cohort

Two-Step: 50 g 1 h; if
≥135 mg/dL:100 g 3 h
GTT

≥135 mg/dL: 100 g
3 h GTT

Not done

Liao et al., 2014
(China) [35]

Retrospective cohort

Two-Step: 50 g 1 h; if
≥140 mg/dL: 100 g
3 h GTT

≥140 mg/dL: 100 g
3 h GTT

Not done

Mayo et al., 2015
(Canada) [36]

Retrospective cohort

Two-Step: 50 g 1 h;
if 140–184 mg/dL:
75 g 2 h GTT

If 140–184 mg/dL:
75 g GTT;
>184 mg/dL: GDM

Meek et al., 2015
(UK) [37]

Retrospective cohort

Two-Step: 50 g 1 h;
if >138 mg/dL: 75 g
2 h GTT

>138 mg/dL: 75 g 2 h
GTT

Tward et al., 2016
(Canada) [38]

Retrospective cohort

Two-Step: 50 g 1 h; if
>140 mg/dL: 75 g 2 h
GTT

≥140 mg/dL: 75 g 2 h
GTT

∗

1 abnormal value of
fasting ≥ 95 mg/dL;
1 h: ≥191 mg/dl: 2 h:
≥160 mg/dL∗
1 abnormal value of
fasting ≥
110/128 mg/dL; 2 h:
≥140 mg/dL∗∗
2 abnormal values of
fasting ≥ 95 mg/dL;
1 h: ≥191 mg/dl: 2 h:
≥160 mg/dL

100 g OGTT criteria
2 abnormal values of
fasting ≥ 95 mg/dL,
or
1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dL
Not done
2 abnormal values of
fasting ≥ 95 mg/dL,
or
1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dL
2 abnormal values of
fasting ≥ 95 mg/dL,
or
1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dL
2 abnormal values of
fasting ≥ 95 mg/dL,
or 1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dL
Not done

Not done

Not done

2008 Canadian Diabetes Association criteria (ref.). ∗∗ WHO 1999 criteria until 2007 (fasting, 148 mg/dL), modified WHO 1999 criteria (fasting, 130 mg/dL).

half used only 1 value and half used 2 values, while any RCT
used less tight criteria (i.e., >50% glucose values higher than
target values) (Table 7) [16, 17, 39–51].
Finally, when analyzing international organizations guidelines on management of GDM, while there is consensus about
glycemic targets, we found different opinions about therapy,
monitoring, and time of delivery (Table 8). Moreover, there is
limited information regarding other important criteria about
dose and frequency of therapy, dose adjustment, and adding
or switching pharmacologic therapy.
Moreover, the application of the IADPSG was associated
with an increase in GDM prevalence up to 3.5-fold, as well
as significant improvements in pregnancy outcomes (gestational hypertension, prematurity, CD, number of LGA and

SGA, and 1-minute Apgar scores <7), and was cost-effective.
This could be presumably by permitting the treatment of a
greater number of women at risk for pregnancy complications
[22].

5. Conclusion
There are many unsolved questions concerning GDM management. Analyzing the literature in detail, we found different criteria for screening for GDM, for monitoring GDM,
and for starting pharmacological therapy. The hope is to
reach universally approved and shared recommendations to
improve health care and reduce costs and adverse outcomes
for women with GDM and their babies.
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Table 6: Continues on the same studies as in Table 5.

Author (origin)

Lapolla et al., 2011 (Italy) [31]

Study group
100 g IADPSG-positive,
C&C-negative
(fasting: 92–94 mg/dL; 2 h:
153-154 mg/dL; not treated)
[𝑛 = 112]

Bodmer-Roy et al., 2012
(Canada) [32]

75 g IADPSG-positive,
CDA-negative
(fasting: 92–95 mg/dL; 1 h:
180–190 mg/dL; 2 h:
153–159 mg/dL; not treated)
[𝑛 = 186]

Benhalima et al., 2013
(Belgium) [33]

100 g IADPSG-positive,
C&C-negative
(fasting: 92–94 mg/dL; 2 h:
153-154 mg/dL; not treated)
[𝑛 = 160]

Ethridge et al., 2014 (USA)
[34]

100 g IADPSG-positive,
C&C-negative
(fasting: 92–94 mg/dL; 2 h:
153-154 mg/dL; not treated)
[𝑛 = 281]

Liao et al., 2014 (China) [35]

100 g IADPSG-positive,
C&C-negative
(fasting: 92–94 mg/dL; 2 h:
153-154 mg/dL; not treated)
[𝑛 = 1314]

Mayo et al., 2015 (Canada)
[36]

75 g IADPSG-positive,
CDA-negative
(fasting: 92–95 mg/dL; 1 h:
180–190 mg/dL; 2 h:
153–159 mg/dL; not treated)
[𝑛 = 155]

Meek et al., 2015 (USA) [37]

75 g IADPSG-positive,
NICE-negative
(fasting: 92–101 mg/dL; 1 h:
≥153 mg/dL; not treated)
[𝑛 = 387]

Tward et al., 2016 (Canada)
[38]

75 g IADPSG-positive,
CDA-negative
(fasting: 92–95 mg/dL; 1 h:
180–190 mg/dL; 2 h:
153–159 mg/dL; not treated)
[𝑛 = 99]

Control
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h:
<153 mg/dL)
[𝑛 = 1815]
GCT-negative (50 g 1 h <
137 mg/dL)
[𝑛 = 186]
Or
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h:
<153 mg/dL)
[𝑛 = 186]
GCT-negative (50 g 1 h <
140 mg/dL)
And
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h:
<153 mg/dL)
[𝑛 = 6345]
GCT-negative (50 g 1 h <
135 mg/dL)
[𝑛 = 6999]
Or
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h:
<153 mg/dL)
[𝑛 = 772]
GCT-negative (50 g 1 h <
140 mg/dL)
And
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h:
<153 mg/dL)
[𝑛 = 2662]
GCT-negative
(50 g 1 h < 140 mg/dL)
[𝑛 = 4183]
Or
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h: <153
mg/dL)
[𝑛 = 526]
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h:
<153 mg/dL)
[𝑛 = 2406]
GCT-negative
(50 g 1 h < 140 mg/dL)
[𝑛 = 1021]
Or
IADPSG-negative
(fasting: <92 mg/dL; 1 h:
<180 mg/dL; 2 h:
<153 mg/dL)
[𝑛 = 184]

Primary outcome

Perinatal outcomes

LGA > 90th percentile

Pregnancy outcomes

Birth weight and neonatal
outcomes

Maternal and neonatal
outcomes

Not stated

Delivery and neonatal
outcomes

Fetal growth in twins
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Table 7: Management of women included in RCTs.

Glucose monitoring

Garner et al., 1997
[39]

Langer et al., 2000
[40]

Mecacci et al., 2003
[41]

Schaefer-Graf et al.,
2004 [42]

4 times daily

A

7 times daily

9 times daily

B

C

6 times dailyD

Crowther et al., 2005
[16]

4 times daily

Anjalakshi et al.,
2007 [43]

Not specified

Landon et al., 2009
[17]

4 times daily

E

E

Target value for
glycemic control

Type of diet

F: <4.4 mmol/l
(80 mg/dL);
1 h: <7.8 mmol/l
(140 mg/dL)

35 kcal/kg IBW/day

Recommendations
about exercise

Glucose values used
for starting
pharmacologic
therapy based on
target values

Not stated

2 or more values
higher in 2 weeks

F: <5.0 mmol/l
(90 mg/dL);
preprandial:
<5.3 mmol/l
(95 mg/dl)
2 h: <6.7 mmol/l
(120 mg/dL)

(i) 25 kcal/kg
BW/day for obese
women
(ii) 35 kcal/kg
BW/day for
nonobese women
(iii) 3 meals and 4
snacks
(iv) 40–45% of
calories from
carbohydrates

Not stated

1 or more
preprandial or 2 h
values higher in 1
week

F: <5.0 mmol/l
(90 mg/dL);
1 h: <6.7 mmol/l
(120 mg/dL)

ADA
recommendations∗

Not stated

More than 50%
values higher after 1
week

Exercise after meals

Intervention group:
(i) AC > 75th 𝑝 < 36
weeks
(ii) F ≥ 120 mg/dL
(iii) 2 h ≥ 200 mg/dL
Control group:
(iv) 2 or more values
(v) 4 profiles with at
least 1 value higher
in 2 weeks

Intervention group:
F: <4.5 mmol/l
(80 mg/dL);
1 h: <6.1 mmol/l
(110 mg/dL)
Control group:
F: <5.0 mmol/l
(90 mg/dL);
1 h: <6.7 mmol/l
(120 mg/dL)

(i) 25 kcal/kg
BW/day for
overweight women
(ii) 30 kcal/kg
BW/day for normal
weight women

F: <5.5 mmol/l
(99 mg/dL);
2 h: <7.0 mmol/l
(126 mg/dL)

Dietary advice from
a qualified dietician

Not stated

(i) 2 values higher in
2 weeks <35 weeks
(ii) 2 h >8.0 mmol/l
(144 mg/dl) in 2
weeks >35 weeks
(iii) 1 value
>9.0 mmol/l
(162 mg/dl) in 2
weeks

2 h: <6.7 mmol/l
(120 mg/dL)

Medical Nutrition
Therapy (MNT)

Not stated

1 value 2 h higher in
2 weeks

Not stated

(i) >50% values
higher between 2
study visits
(ii) 1 random value
>160 mg/dl
(8.9 mmol/l)
(iii) 1 F > 95 mg/dl;
the patient’s
caregiver initiated
treatment (more or
less 7 visits)

F: <5.3 mmol/l
(95 mg/dL);
2 h: <6.7 mmol/l
(120 mg/dL)

ADA
recommendations∗∗
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Table 7: Continued.

Glucose monitoring

F

Ijäs et al., 2011 [44]

4 times daily

Balaji et al., 2012 [45]

4 times dailyE

Mukhopadhyay et
al., 2012 [46]

Niromanesh et al.,
2012 [47]

Silva et al., 2010 [48]

Mesdaghinia et al.,
2013 [49]

Spaulonci et al., 2013
[50]

7 times daily

B

4 times daily

4 times daily

E

A

4 times daily

E

4 times dailyE

Target value for
glycemic control
F: <5.3 mmol/l
(95 mg/dL);
1.5 h: <6.7 mmol/l
(120 mg/dL)
F: <5.0 mmol/l
(90 mg/dL);
2 h: <6.7 mmol/l
(120 mg/dL);
HbA1c: <6.0 g/dL
F: <5.0 mmol/l
(90 mg/dL);
2 h: <6.7 mmol/l
(120 mg/dL)

F: <5.3 mmol/l
(95 mg/dL);
2 h: <6.7 mmol/l
(120 mg/dL)

F: <5.0 mmol/l
(90 mg/dL);
1 h: <6.7 mmol/l
(120 mg/dL)

Type of diet

Dietary and lifestyle
counselling

Medical Nutrition
Therapy (MNT)
(i) 25 kcal/kg BW for
obese women
(ii) 35 kcal/kg BW
for nonobese
women
(iii) 3 daily meals;
40–45% of calories
from carbohydrates
(i) 15 kcal/kg BW for
obese women
(ii) 22 kcal/kg BW
for overweight
women
(iii) 30 kcal/kg BW
for normal weight
women
(iv) 40 kcal/kg BW
for underweight
women
(v) 45% of calories
from carbohydrates,
20% from protein,
and 35% from fat
(vi) 3 meals and 3
snacks
(vii) Calories: 10%
breakfast, 30% each
lunch and dinner,
and 30% snacks
(i) 25 kcal/kg
BW/day for
overweight women
(ii) 35 kcal/kg
BW/day for normal
weight women
(iii) 3 full meals and
4 light meals
(iv) 35–45% of
calories from
carbohydrates

F: <5.3 mmol/l
(95 mg/dL);
2 h: <6.7 mmol/l
(120 mg/dL)

Dietary changes∗∗∗

F: <5.3 mmol/l
(95 mg/dL);
2 h: <6.7 mmol/l
(120 mg/dL)

(i) 25–35 kcal/kg
IBW based on
pregestational BMI
(ii) 55%
carbohydrates, 15%
proteins, and 30% fat

Recommendations
about exercise

Not stated

Glucose values used
for starting
pharmacologic
therapy based on
target values
2 values higher in
2–4 weeks

Not stated

1 value higher in 2
weeks

Not stated

1 value higher in 2
weeks

30 minutes of
walking per day

2 values higher in
one week

Not stated

2 values higher after
1 week

Not stated

1 value higher in 1
week

30-minute walk 3
times a week

>30% values higher
in 1 week
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Table 7: Continued.

Glucose monitoring

Behrashi et al., 2016
[53]

4 times daily

E

Target value for
glycemic control

Type of diet

Recommendations
about exercise

Glucose values used
for starting
pharmacologic
therapy based on
target values

F: <5.0 mmol/l
(90 mg/dL);
2 h: <6.7 mmol/l
(120 mg/dL)

Education for
lifestyle change
(exercise and diet)

Education for
lifestyle change
(exercise and diet)

1 value higher in 1
week

F: fasting; GA: gestational age; IBW: ideal body weight; BW: body weight; BMI: body mass index.
A
Fasting and 1 hour after each main meal: breakfast, lunch, and dinner.
B
Fasting, before lunch and dinner, 2 hours after main meals, breakfast, lunch, and dinner, and at bedtime.
C
Fasting, preprandial before lunch and dinner, 1 and 2 hours after each main meal: breakfast, lunch, and dinner.
D
Fasting, preprandial before lunch and dinner, 1 hour after each main meal: breakfast, lunch, and dinner.
E
Fasting and 2 hours after each main meal: breakfast, lunch, and dinner.
F
Fasting and 1.5 hours after each main meal: breakfast, lunch, and dinner.
∗
American Diabetes Association, Medical Management of Pregnancy Complicated by Diabetes, 3rd Edition, Alexandria, Virginia; ADA, 2000, pp. 70–86.
∗∗
American Diabetes Association, Nutrition Recommendations and Interventions for Diabetes: A Position Statement of the American Diabetes Association;
Diabetes Care 2008 Jan. 31 (Suppl. 1): S61–S78.
∗∗∗
Cheung NW, The Management of Gestational Diabetes: A Review Article; Vasc Health Risk Manag. 2009; 5:153–64.

Table 8: Management of GDM, international guidelines.
ACOG 2013 [4]
Criteria to start
therapy after diet
alone

Inconclusive
evidence

CDA 2013 [10]
Glycemic control
not achieved after 2
weeks of nutritional
therapy alone

ADA 2015 [9]

FIGO 2015 [5]

NICE 2015 [11]
Glycemic control
not achieved after
1-2 weeks of diet and
exercise

NR

NR

Metformin

Type of initial
therapy

Insulin or oral
medications

Insulin or oral
medications

Insulin or glyburide

Glyburide inferior to
both insulin and
metformin,
while metformin
performs
better than insulin

Dose and frequency
of initial therapy

NR

NR

NR

NR

NR

Frequency of glucose
monitoring

4 times
daily as fasting
and either 1 h or 2 h
after each meal

Target glucose values

1 h ≤ 140 mg/dL,
2 h ≤ 120 mg/dL

4 times
daily as fasting
and either 1 h or 2 h
after each meal
Fasting ≤ 95 mg/dL,
1 h ≤ 140 mg/dL,
2 h ≤ 120 mg/dL

Fasting ≤ 95 mg/dL,
1 h ≤ 140 mg/dL,
2 h ≤ 120 mg/dL

4 times
daily as fasting
and 2 h after each
meal
Fasting ≤ 95 mg/dL,
1 h ≤ 140 mg/dL,
2 h ≤ 120 mg/dL

7 times
daily as fasting,
premeal, 1 h after
each meal, bedtime
Fasting ≤ 95 mg/dL,
1 h ≤ 140 mg/dL,
2 h ≤ 116 mg/dL

NR

NR

NR

NR

NR

NR

NR

NR

Criteria for
pharmacologic
NR
therapy dose
adjustment
Criteria for adding or
switching
NR
pharmacologic
therapy

NR

Pregnancy
monitoring

No consensus

NR

NR

NR

Ultrasound
monitoring of fetal
growth and
AF volume every 4
weeks from 28 to 36
weeks

Time to delivery

Well-controlled: >39
weeks; insufficient
data for others; CD
if EFW > 4500 g

NR

NR

Consider induction
at 38-39 weeks

Delivery no later
than 40 + 6 weeks

NR: not reported.
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